These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3409951)

  • 1. Salutary consequences of blockade of platelet activating factor in hemorrhagic shock.
    Stahl GL; Bitterman H; Terashita Z; Lefer AM
    Eur J Pharmacol; 1988 May; 149(3):233-40. PubMed ID: 3409951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial actions of antagonism of peptide leukotrienes in hemorrhagic shock.
    Bitterman H; Smith BA; Lefer AM
    Circ Shock; 1988 Mar; 24(3):159-68. PubMed ID: 3383353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of a platelet activating factor (PAF) antagonist and its combined treatment with prostaglandin (PG) E1 in traumatic shock.
    Terashita Z; Stahl GL; Lefer AM
    J Cardiovasc Pharmacol; 1988; 12(5):505-11. PubMed ID: 2468048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock.
    Stahl GL; Bitterman H; Lefer AM
    Thromb Res; 1989 Feb; 53(3):327-38. PubMed ID: 2718150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of action of PGE1 in hemorrhagic shock in rats.
    Bitterman H; Stahl GL; Terashita Z; Lefer AM
    Ann Emerg Med; 1988 May; 17(5):457-62. PubMed ID: 3364825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial actions of RO 15-1788, a benzodiazepine receptor antagonist, in hemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Methods Find Exp Clin Pharmacol; 1987 Jun; 9(6):341-7. PubMed ID: 3116357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salutary effects of CG-4203, a novel, stable prostacyclin analog, in hemorrhagic shock.
    Bitterman H; Smith BA; Lefer DJ; Lefer AM
    J Cardiovasc Pharmacol; 1988 Sep; 12(3):293-9. PubMed ID: 2464101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock.
    Bitterman H; Yanagisawa A; Lefer AM
    Circ Shock; 1986; 20(1):1-11. PubMed ID: 2945667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock.
    Bitterman H; Lefer DJ; Lefer AM
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Jun; 337(6):679-86. PubMed ID: 3063971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salutary effects of nitrendipine, a new calcium entry blocker, in hemorrhagic shock.
    Hock CE; Su JY; Lefer AM
    Eur J Pharmacol; 1984 Jan; 97(1-2):37-46. PubMed ID: 6698110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
    Bitterman H; Phillips GR; Dragon G; Lefer AM
    J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of arachidonic acid during hemorrhagic shock in the dog.
    Flynn JT; Lefer AM
    Circ Res; 1977 Apr; 40(4):422-8. PubMed ID: 844155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial action of a new opiate antagonist (Win 44,441-3) in hemorrhagic shock.
    Curtis MT; Lefer AM
    Eur J Pharmacol; 1982 Mar; 78(3):307-13. PubMed ID: 6279411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
    Toth PD; Mikulaschek AW
    Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effect of anisodamine in hemorrhagic shock.
    Su J; Hock CE; Lefer AM
    Naunyn Schmiedebergs Arch Pharmacol; 1984 Apr; 325(4):360-5. PubMed ID: 6728045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen therapy in hemorrhagic shock.
    Bitterman H; Reissman P; Bitterman N; Melamed Y; Cohen L
    Circ Shock; 1991 Mar; 33(3):183-91. PubMed ID: 2044210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a role of platelet activating factor in hypovolemic shock in the rat.
    Zingarelli B; Squadrito F; Bussolino F; Calapai G; Altavilla D; Ioculano M; Campo GM; Canale P; Caputi AP
    J Lipid Mediat Cell Signal; 1994 Mar; 9(2):123-34. PubMed ID: 8012759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of CG-4203, a novel stable prostacyclin analog, in traumatic shock.
    Bitterman H; Stahl GL; Lefer AM
    Prostaglandins; 1988 Jan; 35(1):41-50. PubMed ID: 3287456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of AVP in maintenance of circulatory homeostasis during hemorrhagic shock.
    Hock CE; Su JY; Lefer AM
    Am J Physiol; 1984 Feb; 246(2 Pt 2):H174-9. PubMed ID: 6696129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial actions of nalorphine during hemorrhagic shock in cats.
    Hock CE; Curtis MT; Jaffe JS; Lefer AM
    Proc Soc Exp Biol Med; 1983 May; 173(1):76-81. PubMed ID: 6304745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.